The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.

Cancer survivor Zoe Plastiras hopes her message provides some reassurance by highlighting advances in cancer treatment.

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Dan Evans, 19, from Newark in Nottinghamshire, described his huge relief ringing the "cancer-free bell" at the teenage cancer ...

An emotional two-year journey reached a heart-warming milestone as Newark’s miracle boy, who defied all the odds to ring his ...

Oct. 17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy nivolumab to a current treatment regimen.

Concurrently, mediastinal lymphadenopathy was observed. Given the suspicion of mediastinal lymphoma, a mediastinoscopy with lymph node biopsy was performed. Following a negative biopsy result, ...

Although usually identified early, skin lymphomas can be mistaken for other skin conditions, delaying diagnosis. Non-Hodgkin's lymphoma (NHL) occurs when lymphocytes called T cells and B cells become ...

The American Cancer Society’s most recent estimates for all types of non-Hodgkin lymphoma (NHL) in the United States for 2025 are: 80,350 new cases of NHL (45,140 in men and 35,210 in women) 19,390 ...

Breyanzi ® offers diffuse large B-cell lymphoma patients facing relapse or refractory disease earlier access with more personalized second-line treatment options. In the pivotal Phase 3 TRANSFORM ...

T-cell lymphoma is a type of lymphatic cancer that starts in the T lymphocytes (T cells), a type of white blood cell. T lymphocytes (T cells) and B lymphocytes (B cells) are two types of white blood ...